263 related articles for article (PubMed ID: 11578285)
1. Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma.
Crombie N; Rampaul RS; Pinder SE; Elston CW; Robertson JF; Ellis IO
Br J Surg; 2001 Oct; 88(10):1324-9. PubMed ID: 11578285
[TBL] [Abstract][Full Text] [Related]
2. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
Padmore RF; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky AS
Cancer; 2000 Mar; 88(6):1403-9. PubMed ID: 10717623
[TBL] [Abstract][Full Text] [Related]
3. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
4. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
[TBL] [Abstract][Full Text] [Related]
5. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
Fodor J
Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
[TBL] [Abstract][Full Text] [Related]
6. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
8. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
[TBL] [Abstract][Full Text] [Related]
9. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
10. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
11. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
[TBL] [Abstract][Full Text] [Related]
12. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
[TBL] [Abstract][Full Text] [Related]
13. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
14. Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?
Yerushalmi R; Sulkes A; Mishaeli M; Neumann A; Dinerman M; Sulkes J; Rizel S; Yarom N; Gutman H; Fenig E
Neoplasma; 2006; 53(6):507-10. PubMed ID: 17167720
[TBL] [Abstract][Full Text] [Related]
15. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?
Chagpar AB; McMasters KM; Sahoo S; Edwards MJ
Surgery; 2009 Oct; 146(4):561-7; discussion 567-8. PubMed ID: 19789013
[TBL] [Abstract][Full Text] [Related]
16. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
17. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma.
Sakr R; Antoine M; Barranger E; Dubernard G; Salem C; Daraï E; Uzan S
Breast J; 2008; 14(1):55-60. PubMed ID: 18186866
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
20. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]